- Home
- XYF vs ENGN Comparison
XYF vs ENGN Comparison
Compare XYF & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XYF
- ENGN
- Stock Information
- Founded
- XYF 2014
- ENGN 1999
- Country
- XYF China
- ENGN Canada
- Employees
- XYF N/A
- ENGN N/A
- Industry
- XYF Finance: Consumer Services
- ENGN
- Sector
- XYF Finance
- ENGN
- Exchange
- XYF Nasdaq
- ENGN Nasdaq
- Market Cap
- XYF 708.7M
- ENGN 204.3M
- IPO Year
- XYF 2018
- ENGN N/A
- Fundamental
- Price
- XYF $19.00
- ENGN $3.83
- Analyst Decision
- XYF
- ENGN Buy
- Analyst Count
- XYF 0
- ENGN 7
- Target Price
- XYF N/A
- ENGN $23.29
- AVG Volume (30 Days)
- XYF 287.2K
- ENGN 97.4K
- Earning Date
- XYF 08-20-2025
- ENGN 06-12-2025
- Dividend Yield
- XYF 2.65%
- ENGN N/A
- EPS Growth
- XYF 32.83
- ENGN N/A
- EPS
- XYF 4.76
- ENGN N/A
- Revenue
- XYF $909,710,294.00
- ENGN N/A
- Revenue This Year
- XYF N/A
- ENGN N/A
- Revenue Next Year
- XYF N/A
- ENGN N/A
- P/E Ratio
- XYF $3.99
- ENGN N/A
- Revenue Growth
- XYF 31.55
- ENGN N/A
- 52 Week Low
- XYF $3.78
- ENGN $2.65
- 52 Week High
- XYF $19.80
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- XYF 62.37
- ENGN 57.73
- Support Level
- XYF $16.10
- ENGN $2.95
- Resistance Level
- XYF $17.65
- ENGN $3.44
- Average True Range (ATR)
- XYF 0.90
- ENGN 0.26
- MACD
- XYF 0.03
- ENGN 0.08
- Stochastic Oscillator
- XYF 100.00
- ENGN 82.86
About XYF X Financial each representing six
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.